Category: New products
-
Home V.R. Therapy Shown to Reduce Back Pain
A virtual reality program conducted at home is shown in a clinical trial to relieve chronic lower back pain intensity and improve daily living more than a sham V.R. program.
-
Electric Pulses Induce Lung Cancer Immune Response
Results of a clinical trial show a lung cancer therapy using highly focused pulses with electrical energy show signs of immune responses that can treat the patients’ tumors.
-
Merger to Form Programmable Nano-Medicines Company
A life science venture investor is merging two of its biotechnology portfolio companies to form a single developer of nanoscale medications with programmable properties.
-
Organ Chip Devices to Model for Radiation Sickness
The U.S. government’s health preparedness agency awarded a contract with a university lab to explore organ models on chips to document effects of radiation sickness.
-
Start-Up Adapts Crispr for Molecular Detection, Raises $40M
A new company is underway that says it adapts the gene editing technique Crispr to make detecting nucleic acid targets like DNA or RNA faster and simpler.
-
High-Speed Biologic Injection Device Shown Feasible
A developer of an auto-injection technology says its device can deliver a biologic drug under the skin in a fraction of the time of conventional syringes.
-
Genetic Tests of Breast Cancer Patients Shown Useful
Experiences from a rural hospital in North Carolina show hereditary genetic testing of all breast cancer patients is feasible and can result in changes in care for many patients.
-
Longevity Science Group Spins-Off Biotech Start-Up
An organization funding research on extending the human life span by preventing age-related diseases is founding its first biotechnology company.
-
Collapsed Microbiome Biotech Sells Off Assets
A developer of therapies addressing the body’s microbe communities is selling off key assets to another biotechnology company, after problems developed with its lead program.
-
Neuro Disease Biotech Gains $61M in Early Funds
A developer of treatments for Alzheimer’s disease that seeks to improve the condition of the brain’s support cells is raising £48 million ($US 61 million) in its first venture round.